Navigation Links
Climate model links higher temperatures to prehistoric extinction

bone marrow.

In the in vitro portion of the study, researchers used mouse bone marrow cells containing the stem cells that give rise to mast cells. They cultured these precursor cells in conditions that allow mast cells to develop, and then added IFNγ to some of these cultures. A high rate of cell death yielding no living mast cells was observed in the cultures that received IFNγ.

Similar results were reported in vivo using a mouse model. Mice with a mutation that causes them to overproduce IFNγ were used, and again, researchers observed a significant decrease in mast cell numbers due to the excess of IFNγ. When researchers tried to culture mast cells from the bone marrow of these mice, the mast cells died.

Furthermore, a separate strain of mice with the same mutation as the first strain, but that had also been engineered to prevent IFNγ production, were found to have almost as many mast cells as normal mice, if not more. They concluded that the presence of high IFNγ levels blocked mast cell development.


'"/>

Source:NSF Public Affairs


Page: 1 2

Related biology news :

1. Climate change will affect carbon sequestration in oceans, model shows
2. Climate change: The rice genome to the rescue
3. Climate change drives widespread amphibian extinctions
4. Climate change has surprising effect on endangered naked carp
5. Climate experts search for answers in the oceans
6. Climate change creates dramatic decline in red-winged black bird population
7. Climate change could trigger boom and bust population cycles leading to extinction
8. Climate change impacts stream life
9. Climate change was the cause of Neanderthal extinction in the Iberian Peninsula
10. Scientists identify new model Of NK cell development
11. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data
Post Your Comments:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5